N Recombinant Monoclonal Antibody, HRP conjugated

Code CSB-RA33255B1GMY
Size US$210
Order now
Image
  • The Binding Activity of SARS-CoV-2-N Antibody-N Antibody, HRP conjugated with SARS-CoV-2-N
    Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-N (CSB-EP3325GMY) at 2 μg/ml can bind SARS-CoV-2-N Antibody, HRP conjugated, the EC50 is 188.35 ng/ml.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
N (Nucleoprotein)
Alternative Names
N; Nucleoprotein; N; Nucleocapsid protein; NC; Protein N
Species Reactivity
Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV)
Immunogen
Recombinant Human Novel Coronavirus Nucleoprotein (N) (1-419aa) CSB-EP3325GMY
Immunogen Species
Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV)
Conjugate
HRP
Clonality
Monoclonal
Isotype
Mouse scFv fusion with human IgG1 Fc
Clone No.
1A6
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The production of the N recombinant monoclonal antibody involves a systematic process to ensure its high quality and specific binding properties. The journey begins by isolating B cells from the spleen of an immunized animal, where the recombinant human SARS-CoV-2 N protein (1-419aa) is used as the immunogen. RNA is then extracted from these B cells and converted into cDNA through reverse transcription. The N antibody genes are amplified using specific primers designed for the antibody constant regions and cloned into an expression vector. The human IgG1 Fc is inserted into the vector, downstream of the N antibody gene and the HRP is also incorporated into the vector. This recombinant vector is introduced into host cells through transfection, allowing for the production of the N recombinant monoclonal antibody. After an appropriate incubation period, the antibody is collected from the cell culture supernatant and purified using affinity chromatography to ensure a highly pure form. The purified N recombinant monoclonal antibody is characterized using ELISA analysis to validate its specificity and functionality in detecting human SARS-CoV-2 N protein. Through this comprehensive production process, a reliable and effective N recombinant monoclonal antibody is generated, making it an invaluable tool for various SARS-CoV-2-associated research.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. May modulate transforming growth factor-beta signaling by binding host smad3.
Subcellular Location
Virion. Host cytoplasm.
Protein Families
Betacoronavirus nucleocapsid protein family
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*